NCT02974907View on ClinicalTrials.gov

Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome : ARISE-2

PHASE3CompletedINTERVENTIONAL
Enrollment

601

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

September 30, 2017

Study Completion Date

March 31, 2018

Conditions
Dry Eye Syndrome
Interventions
DRUG

RGN-259

A preservative-free, sterile eye drop solution containing Tβ4 for direct instillation into each eye, four times a day (QID) for 28 days

DRUG

Placebo

It is composed of the same excipients as RGN-259 but does not contain Tβ4

Trial Locations (1)

01810

Andover, MA, Andover

All Listed Sponsors
lead

ReGenTree, LLC

INDUSTRY

NCT02974907 - Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome : ARISE-2 | Biotech Hunter | Biotech Hunter